Bicara Therapeutics (BCAX) Competitors $11.90 -0.04 (-0.34%) Closing price 04:00 PM EasternExtended Trading$11.90 -0.01 (-0.04%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. CPRX, ALVO, KNSA, OGN, TARS, CNTA, DNLI, AGIO, IDYA, and IBRXShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors Catalyst Pharmaceuticals Alvotech Kiniksa Pharmaceuticals International Organon & Co. Tarsus Pharmaceuticals Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals IDEAYA Biosciences ImmunityBio Catalyst Pharmaceuticals (NASDAQ:CPRX) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Do analysts recommend CPRX or BCAX? Catalyst Pharmaceuticals currently has a consensus price target of $33.20, suggesting a potential upside of 61.64%. Bicara Therapeutics has a consensus price target of $32.25, suggesting a potential upside of 171.02%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalyst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is CPRX or BCAX more profitable? Catalyst Pharmaceuticals has a net margin of 37.36% compared to Bicara Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Catalyst Pharmaceuticals37.36% 40.78% 35.36% Bicara Therapeutics N/A -21.67%-20.89% Do institutionals & insiders hold more shares of CPRX or BCAX? 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, CPRX or BCAX? Catalyst Pharmaceuticals has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalyst Pharmaceuticals$491.73M5.11$163.89M$1.6512.45Bicara TherapeuticsN/AN/A-$68M-$3.17-3.75 Does the media refer more to CPRX or BCAX? In the previous week, Catalyst Pharmaceuticals had 16 more articles in the media than Bicara Therapeutics. MarketBeat recorded 19 mentions for Catalyst Pharmaceuticals and 3 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.05 beat Catalyst Pharmaceuticals' score of 0.94 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCatalyst Pharmaceuticals beats Bicara Therapeutics on 12 of the 15 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$649.26M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-3.7520.9982.6526.40Price / SalesN/A396.26529.10204.59Price / CashN/A43.5325.7028.92Price / Book1.329.8811.246.06Net Income-$68M-$53.38M$3.28B$266.05M7 Day Performance-1.16%-0.14%0.15%-0.07%1 Month Performance13.01%9.18%8.36%5.83%1 Year PerformanceN/A7.53%54.25%17.89% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara TherapeuticsN/A$11.90-0.3%$32.25+171.0%N/A$649.26MN/A-3.7532News CoveragePositive NewsCPRXCatalyst Pharmaceuticals4.8946 of 5 stars$20.62-2.2%$33.20+61.0%+1.7%$2.58B$491.73M12.5080ALVOAlvotech2.9134 of 5 stars$8.32-1.5%$14.00+68.3%-30.9%$2.55B$491.98M36.171,032Positive NewsShort Interest ↑KNSAKiniksa Pharmaceuticals International2.8612 of 5 stars$33.04-2.1%$41.17+24.6%+25.2%$2.50B$529.33M826.21220News CoveragePositive NewsAnalyst DowngradeOGNOrganon & Co.4.8411 of 5 stars$9.08-3.8%$18.00+98.3%-58.0%$2.45B$6.40B3.374,000Positive NewsTARSTarsus Pharmaceuticals1.9664 of 5 stars$56.61-1.1%$66.67+17.8%+116.1%$2.42B$182.95M-24.3050News CoveragePositive NewsCNTACentessa Pharmaceuticals2.614 of 5 stars$17.00-0.1%$28.10+65.3%+24.4%$2.28B$6.85M-9.50200News CoveragePositive NewsDNLIDenali Therapeutics4.2475 of 5 stars$15.57+0.5%$33.62+115.9%-37.5%$2.26B$330.53M-5.56430News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3173 of 5 stars$37.26-4.0%$56.33+51.2%-17.9%$2.25B$36.50M3.39390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4024 of 5 stars$24.71-1.6%$48.09+94.6%-37.8%$2.20B$7M-6.5280News CoveragePositive NewsGap UpIBRXImmunityBio2.4358 of 5 stars$2.25-2.6%$10.75+377.8%-40.8%$2.18B$14.74M-4.69590 Related Companies and Tools Related Companies CPRX Competitors ALVO Competitors KNSA Competitors OGN Competitors TARS Competitors CNTA Competitors DNLI Competitors AGIO Competitors IDYA Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
